Role of cytokines in transplantation tolerance: Lessons learned from gene-knockout mice

Journal of the American Society of Nephrology

Volumn 9, Issue 12, 1998, Pages 2361-2367

  Lakkis, Fadi G ^a,b  

^a EMORY UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HELPER CELL; IMMUNOLOGICAL TOLERANCE; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

EID: 0031755722     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Charlton B, Auchincloss H Jr, Fathman CG: Mechanisms of transplantation tolerance. Annu Rev Immunol 12: 707-734, 1994
2. Kruisbeek AK, Amsen D: Mechanisms underlying T-cell tolerance. Curr Opin Immunol 8: 233-244, 1996
3. Lechler R, Bluestone JA: Transplantation tolerance: Putting the pieces together. Curr Opin Immunol 9: 631-633, 1997
4. Smith JA, Bluestone JA: T cell inactivation and cytokine deviation promoted by anti-CD3 antibodies. Curr Opin Immunol 9: 648-654, 1997
5. Wood KJ, Pearson TS, Darby C, Morris PJ: CD4: A potential target molecule for immunosuppressive therapy and tolerance induction. Transplantation 55: 150-156, 1991
6. Magee CC, Sayegh MH: Peptide-mediated immunosuppression. Curr Opin Immunol 9: 669-675, 1997
7. Lin H, Boiling SF, Linsley PS, Wei R-Q, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 178: 1801-1806, 1993
8. Nikolic B, Sykes M: Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol 9: 634-640, 1997
9. Sayegh MH, Turka LA: T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 6: 1143-1150, 1995
10. Larsen CP, Pearson TC: The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 9: 641-647, 1997
11. Abbas AK, Lichtman AH, Pober JS: Cytokines. In: Cellular and Molecular Immunology, 3rd Ed., Philadelphia, Saunders, 1997, pp 249-277
12. Dallman MJ: Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 5: 788-793, 1993
13. Dallman MJ: Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol 7: 632-638, 1995
14. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 383: 787-793, 1996
15. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996
16. O'Garra A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8: 275-283, 1998
17. Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB: Cytokines and Th1/Th2 paradigm in transplantation. Curr Opin Immunol 6: 757-764, 1994
18. Takeuchi T, Lowry RP, Konieczny B: Heart allografts in murine systems. Transplantation 53: 1281-1294, 1992
19. O'Connell PJ, Pacheco-Silva A, Nickerson PW, Muggia RA, Bastos M, Rubin-Kelley V, Strom TB: Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 150: 1093-1104, 1993
20. Kupiec-Weglinski JW, Wasowska B, Papp I, Schmidbauer G, Sayegh MH, Baldwin WM III, Wieder KJ, Hancock WW: CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol 151: 5053-5061, 1993
21. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 181: 1869-1874, 1995
22. Field EH, Gao Q, Chen NX, Rouse TM: Balancing the immune system for tolerance: A case for regulatory CD4 cells. Transplantation 64: 1-7, 1997
23. Picotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK: Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 63: 619-624, 1997
24. Debets R, Savelkoul HF: Cytokine antagonists and their potential therapeutic use. Immunol Today 15: 455-458, 1994
25. Capecchi MR: Altering the genome by homologous recombination. Science 244: 1288-1292, 1989
26. Pfeffer K, Mak TW: Lymphocyte ontogeny and activation in gene targeted mutant mice. Annu Rev Immunol 12: 367-411, 1994
27. Steinman L: Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med 185: 2039-2041, 1997
28. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352: 621-624, 1991
29. Kuhn R, Rajewsky K, Muller W: Generation and analysis of interleukin-4 deficient mice. Science 254: 707-710, 1991
30. Kopf M, Gros GL, Bachmann M, Lamers MC, Bluethmann H, Kohler G: Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362: 245-248, 1993
31. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart T: Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259: 1739-1742, 1993
32. Steiger B, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom JB: IL-2 knockout recipient mice reject islet cell allo-grafts. J Immunol 155: 489-498, 1995
33. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG: Impaired alloantigen-mediated T cell apoptosis and failure to induce long term allograft survival in IL-2-deficient mice. J Immunol 161: 1659-1663, 1998
34. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB: Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 83: 2624-2627, 1986
35. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161-165, 1998
36. Nickerson P, Steiger J, Zheng XX, Steele AW, Steurer W, Roy-Chaudhury P, Strom TB: Manipulation of cytokine networks in transplantation: False hope or realistic opportunity for tolerance? Transplantation 63: 489-494, 1997
37. Fanslow WC, Clifford KN, Park LS, Rubin AS, Voice RF, Beckman MP, Widmer MB: Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 147: 535-540, 1991
38. Nickerson P, Zheng X, Steiger J, Steele A, Steurer W, Roy-Chaudhury P, Muller W, Strom T: Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transplant Immunol 4: 81-85, 1996
39. Lakkis FG, Konieczny BT, Saleem S, Baddoura FK, Linsley PS, Alexander DZ, Lowry RP, Pearson TC, Larsen CP: Blocking the CD28-B7 T cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of interleukin-4. J Immunol 158: 2443-2448, 1997
40. Roy-Chaudhury P, Manfro RC, Steiger J, Nickerson PW, Zheng XX, Tian Y, Li YS, Strom TB: IL-2 + IL-4 double knockout (DKO) mice reject islet allografts: A role for IL-7 and IL-15? [Abstract] J Am Soc Nephrol 7: 1893A, 1996
41. Taniguchi T, Minami Y: The IL-2/IL-2 receptor system: A current overview. Cell 73: 5-8, 1993
42. c)- dependent cytokines: Understanding in vivo functions by gene targeting. Immunol Rev 148: 19-34, 1995
43. Billiau A: Interferon-γ: Biology and role in pathogenesis. Adv Immunol 62: 61-130, 1996
44. Saleem S, Konieczny BT, Lowry RP, Baddoura FK, Lakkis FG: Acute rejection of vascularized heart allografts in the absence of IFNγ. Transplantation 62: 1908-1911, 1996
45. Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley P, Baddoura FK, Larsen CP, Pearson TC, Lakkis FG: IFNγ is critical for long term allograft survival induced by blocking the CD28 and CD40L T cell costimulation pathways. J Immunol 160: 2059-2064, 1998
46. Steiger JU, Nickerson PW, Hermle M, Thiel G, Heim MH: Interferon-gamma receptor signaling is not required in the effector phase of the alloimmune response. Transplantation 65: 1649-1652, 1998
47. Stevens HPJD, Van der Kwast TH, Van der Meide P, Vuzevski VD, Buurman WA, Jonker M: Synergistic immunosuppression effects of monoclonal antibodies specific for interferon-γ and tumor necrosis factor-α. Transplantation 50: 856-861, 1990
48. Rosenberg AS, Finbloom DS, Maniero TG, Van der Meide PH, Singer A: Specific prolongation of MHC class 2 disparate skin allografts by in vivo administration of anti-IFN-γ monoclonal antibody. J Immunol 144: 4648-4650, 1990
49. Saleem S, Konieczny BT, Baddoura FK, Lakkis FG: Interferon-gamma (IFNγ) is necessary for acute rejection of MHC class II-disparate skin allografts but is not required for MHC class I rejection [Abstract]. J Am Soc Nephrol 8: 664A, 1997
50. Qin S, Cobbold S, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H: "Infectious" transplantation tolerance. Science 259: 974-977, 1993
51. Onodera K, Lehmann M, Akalin E, Volk H-D, Sayegh MH, Kupiec-Weglinski JW: Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 157: 1944-1950, 1996
52. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H: T cell regulation in adult transplantation tolerance. J Immunol 157: 529-533, 1996
53. Gao Q, Chen N, Rouse TM, Field EH: The role of IL-4 in the induction phase of allogeneic neonatal tolerance. Transplantation 62: 1847-1852, 1996
54. Chen N, Gao Q, Field EH: Prevention of TH1 responses is critical for tolerance. Transplantation 61: 1076-1083, 1996
55. Mueller R, Davies JD, Krahl T, Sarvetnick N: IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J Immunol 159: 1599-1603, 1997
56. Takeuchi T, Ueki T, Sunaga S, Ikuta K, Sasaki Y, Li B, Moriyama N, Miyazaki J-I, Kawabe K: Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of the TH1 cytokine mRNA in grafts. Transplantation 64: 152-157, 1997
57. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB: Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 154: 5590-5600, 1995
58. Suthanthiran M: Molecular analyses of human renal allografts: Differential intragraft gene expression during rejection. Kidney Im Suppl 58: S15-S21, 1997
59. Picotti JR, Chan SY, Li K, Eichwald EJ, Bishop DK: Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4+ and CD8+ IFN-gamma-producing cells. J Immunol 158: 643-648, 1997
60. Boehm U, Klamp T, Groot M, Howard J: Cellular responses to interferon-γ. Annu Rev Immunol 15: 749-795, 1997
61. Smith KA: Interleukin-2: Inception, impact, and implications. Science 240: 1169-1176, 1988
62. Kweon MN, Fujihashi K, VanCott JL, Higuchi K, Yamamoto M, McGhee JR, Kiyono H: Lack of orally induced systemic unresponsiveness in IFN-γ knockout mice. J Immunol 160: 1687-1693, 1998
63. Van-Parijs L, Biuckians A, Ibragimov A, Alt FW, Willerford DM, Abbas AK: Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J Immunol 158: 3738-3745, 1997
64. Kneitz B, Herman T, Yonehara S, Schimpl A: Normal clonal expansion but impaired Fas-mediated cell death and anergy in IL-2 deficient mice. Eur J Immunol 25: 2572-2577, 1995
65. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier M-C, Fournier C: High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J Immunol 158: 5501-5506, 1997
66. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P: Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J Immunol 158: 5507-5513, 1997
67. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG: Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156: 5-7, 1996
68. Willenborg DO, Fordham S, Bernard CCA, Cowden WB, Ramshaw IA: IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157: 3223-3227, 1996
69. Matthys P, Froyen G, Verdot L, Huang S, Sobis H: Van Damme J, Vray B, Aguet M, Billiau A: IFN-γ receptor-deficient mice are hypersensitive to the anti-CD3-induced cytokine release syndrome and thymocyte apoptosis: Protective role of endogenous nitric oxide. J Immunol 155: 3823-3829, 1995
70. Wall DA, Hamberg SD, Burakoff SJ, Reynolds DS, Abbas AK, Ferrara LM: Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J Immunol 140: 2970-2976, 1988
71. Horak I, Lohler J, Ma A, Smith KA: Interleukin-2 deficient mice: A new model to study autoimmunity and self-tolerance. Immunol Rev 148: 35-44, 1995
72. Theze J, Alzari PM, Bertoglio J: Interleukin 2 and its receptors: Recent advances and new immunological functions. Immunol Today 17: 481-486, 1996
73. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25: 3053-3059, 1995
74. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261, 1993
75. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJL, Ohashi PS, Griesser H, Taniguchi T, Paige CJ, Mak TW: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268: 1472-1476, 1995
76. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW: Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3: 521-530, 1995
77. Lenardo MJ: Interleukin-2 programs mouse alpha/beta T lymphocytes for apoptosis. Nature 353: 858-861, 1991
78. Boehme SA, Lenardo MJ: Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 23: 1552-1560, 1993
79. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ: T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263: 1139-1143, 1994
80. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176: 1595-1604, 1992
81. Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183: 2533-2540, 1996
82. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183: 2541-2550, 1996
83. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417, 1997